These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15535042)

  • 1. [Development of software for data analysis by therapeutic drug monitoring of teicoplanin, a glycopeptide antibiotic].
    Niwa T; Tokuma Y; Ito T; Kimura J; Tabata K; Takagi A
    Jpn J Antibiot; 2004 Aug; 57(4):413-9. PubMed ID: 15535042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of new software (Ver. 2.0) based on the Bayesian estimation utilized in the therapeutic drug monitoring of teicoplanin, a glycopeptide antibiotic].
    Niwa T; Tabata K; Kimura J; Kamada M; Noda Y; Takagi A
    Jpn J Antibiot; 2006 Jun; 59(3):165-76. PubMed ID: 16913403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.
    Kanazawa N; Matsumoto K; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2011 Apr; 17(2):297-300. PubMed ID: 20714913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring based on early measurements of serum teicoplanin levels in Japanese patients.
    Oda K; Kasada T; Yoshikawa M; Tanoue M; Yamashita T; Takeshita Y
    Ther Drug Monit; 2014 Jun; 36(3):401-5. PubMed ID: 24270046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection.
    Ogawa R; Kobayashi S; Sasaki Y; Makimura M; Echizen H
    Int J Clin Pharmacol Ther; 2013 May; 51(5):357-66. PubMed ID: 23458228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.
    Thalhammer F; Rosenkranz AR; Burgmann H; Graninger W; Hollenstein U; Schenk P; Thalhammer-Scherrer R; Traindl O; Hörl WH; Breyer S
    Wien Klin Wochenschr; 1997 May; 109(10):362-5. PubMed ID: 9200809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bayesian approach to drug disposition evaluation: application to teicoplanin.
    Ferrante L; Bompadre S; Cingolani ML; Leone L
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):410-4. PubMed ID: 7582399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teicoplanin pharmacokinetics in patients with chronic renal failure.
    Bonati M; Traina GL; Villa G; Salvadeo A; Gentile MG; Fellin G; Rosina R; Cavenaghi L; Buniva G
    Clin Pharmacokinet; 1987 Apr; 12(4):292-301. PubMed ID: 2954735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.
    Zhao W; Zhang D; Storme T; Baruchel A; Declèves X; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2015 Nov; 80(5):1197-207. PubMed ID: 26138279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
    Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use and therapeutic drug monitoring of teicoplanin in the UK.
    Darley ES; MacGowan AP
    Clin Microbiol Infect; 2004 Jan; 10(1):62-9. PubMed ID: 14706088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose.
    Pea F; Brollo L; Viale P; Pavan F; Furlanut M
    J Antimicrob Chemother; 2003 Apr; 51(4):971-5. PubMed ID: 12654757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Level of evidence for therapeutic drug monitoring of teicoplatin].
    Boulamery A; Venisse N; Le Guellec C;
    Therapie; 2011; 66(1):45-50. PubMed ID: 21466777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme.
    Lamont E; Seaton RA; Macpherson M; Semple L; Bell E; Thomson AH
    J Antimicrob Chemother; 2009 Jul; 64(1):181-7. PubMed ID: 19411678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teicoplanin population pharmacokinetic analysis in hospitalized patients.
    Soy D; López E; Ribas J
    Ther Drug Monit; 2006 Dec; 28(6):737-43. PubMed ID: 17164688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inter-individual and intra-individual pharmacokinetic variability during teicoplanin therapy in geriatric patients].
    Uhart M; Leroy B; Michaud A; Maire P; Bourguignon L
    Med Mal Infect; 2013 Jul; 43(7):295-8. PubMed ID: 23906420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic parameters of vancomycin in critically ill patients.
    Llopis-Salvia P; Jiménez-Torres NV
    J Clin Pharm Ther; 2006 Oct; 31(5):447-54. PubMed ID: 16958822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens.
    Hu S; Wang T; You H; Wei S; Song H; Zhang T; Zhang D; Dong Y
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):594-601. PubMed ID: 29702731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics and Pharmacodynamics of Teicoplanin and C-Reactive Protein in Hospitalized Patients With Gram-Positive Infections.
    Ogami C; Tsuji Y; Muraki Y; Mizoguchi A; Okuda M; To H
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):175-188. PubMed ID: 30934169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study.
    Roberts JA; Stove V; De Waele JJ; Sipinkoski B; McWhinney B; Ungerer JP; Akova M; Bassetti M; Dimopoulos G; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Lipman J;
    Int J Antimicrob Agents; 2014 May; 43(5):423-30. PubMed ID: 24630304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.